TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Subjects Who Experienced at Least One Serious Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline intraocular pressure at first day postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline intraocular pressure at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline intraocular pressure at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline intraocular pressure at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline intraocular pressure at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-abdominal Pressure Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Attempts Before Entering Trachea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Assisting Hand Assessment after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jebsen-Taylor Test of Hand Function after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Box and blocks test after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of the mask in the operating room
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Discrimination between Malignant and Benign Gastric Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Unanticipated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Difference between in-brace curve correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Out-of-brace Cobb angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour Point-prevalence tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of cervix visualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with > 50% seizure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in 10-year absolute CHD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in lipidomic composition of plasma post-prandial lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Receiving Antibacterial Agents (Empirical)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Receiving Antibacterial Agents (Targeted)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Onset of Composite Confirmed Disability Progression (cCDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cerebral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mucosal cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Line infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression to esophageal adenocarcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Successful liberation from invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in lung function following exercise challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sputum biomarkers of lung inflammation and remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Childhood Trauma Questionnaire (CTQ) for childhood trauma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Voxel-based morphometry (VBM) for total gray matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Voxel-based morphometry (VBM) for regional gray matter density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinal sensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Excretion of Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fecal Excretion of Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Predicted therapeutic outcome of OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response of choroidal neovascularisation to Lucentis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean change from Baseline in cognitive processing speed scores on the Symbol Digit Modalities Test at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change from Baseline in sustained attention scores on the Continuous Performance Test at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change from Baseline in working memory scores on the Digit Span-Backward Test at 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to achieve SBP target range (110-140)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in ADHD Rating Scale Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: stroke/systemic embolism event
Endpoint domain: Mortality/survival
Primary endpoint: major bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Composite rate of all-cause mortality, stroke and rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Time to infusion set failure due to occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of zilovertamab vedotin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Sensitivity
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Specificity
Endpoint domain: Mortality/survival
Primary endpoint: Positive Predictive Value
Endpoint domain: Mortality/survival
Primary endpoint: Functional MRI activity during a motor task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 17-hydroxyprogesterone/cortisol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pediatric Crohn's Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of blood FSH R detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of genitourinary fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to open eyes under investigator's command
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Pain Free Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability expressed in treatment related (serious) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate and time of onset of high degree or complete AVB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of arrhythmic events leading to a change in treatment or major adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of salivary test vs. nasopharyngeal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant findings on physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant findings in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or Higher Non-hematological Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic Congestive Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peri-implantitis risk profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusion rate of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RDT performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragmatic Thickness fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Growth rate for weight (g/kg/day) from birth to 36+0 weeks CGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth rate for length (cm/week) from birth to 36+0 weeks CGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth rate for head circumference (cm/week) from birth to 36+0 weeks CGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Dosage Errors
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impressions - Severity Scale (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in QRS Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to First Cardiovascular Hospitalization or Death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission and SDAI Low Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Good to Moderate European League Against Rheumatism (EULAR) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of HQP1351
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of HQP1351
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Adenomas and Hyperplastic Polyps Missed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain intensity at various time points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage open grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Change from Baseline in Pain Scores on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change from Baseline in Maximal Oral Opening Scores (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change from Baseline in Oral Health Impact Profile-14 Spanish Version (OHIP-14sp) questionnaire Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Depressive Symptoms at 11 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depressive Symptoms at 19 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Caregiver Burden - Zarit
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Caregiver Burden - Time Required
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Caregiver Burden - Task Difficulty
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Presence/absence of an activation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (AUC, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of elimination (% TRA recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral hyperperfusion syndrome or cerebral hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Perceived effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIT-6
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 6-month Clinical Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of mammography screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Safely Received AMD3100 Used in Combination With Standard Dose G-CSF
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants for Whom a Sufficient Number of CD34+ Cells Were Mobilized Into the Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Skin flora reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in fecal calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of IN10018
Endpoint domain: Adverse events/effects
Primary endpoint: Growth and development of the pediatric craniofacial skeleton
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Center for Neurologic Study-Lability Scale (CNS-LS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scores on the Clinical Global Impression of Severity of Illness (CGIS) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scores on the Clinical Global Impression of Change (CGIC) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Systolic Velocity Ratio (PSVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: partial response rate of intracranial lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neurotoxic
Endpoint domain: Adverse events/effects
Primary endpoint: Blood loss equal or more than 1000 ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of additional uterotonics
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Meet HIV-1- RNA Viral Load >50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ T-Cell Counts < 200 Cells/mm^3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of New or Recurrent Opportunistic Infections or HIV-Associated Malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Number of unscheduled doctor visits for dyspnea and wheezing
Endpoint domain: Adverse events/effects
Primary endpoint: Complete response rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Hamilton Anxiety Rating Scale (HAM-A) total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of circulating endothelial cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Strength of intratumoral blood perfusion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax for anti-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical jump height change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation or Intensification of Guideline-Directed Medical Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bayley III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of newly-onset adrenal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Primary patency of AV fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Alcohol consumption in units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast Sensitivity Function (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of lumbar and/or abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change in average number of steps taken per day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of NTM lung disease
Endpoint domain: Mortality/survival
Primary endpoint: Avoidance of Intubation at 28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 5-year cumulative incidence of in-breast cancer recurrences
Endpoint domain: Mortality/survival
Primary endpoint: Financial toxicity of cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative recurrent rate
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of anakinra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Post Dural Puncture Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difficulty of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of HIV and non-HIV related clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Grade 3 Through Grade 5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of shoulder hand syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the modified Barthel index (MBI) and MBI efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Fugl-Meyer Assessment (FMA) (upper limb) and FMA efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-traumatic amputate events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinically significant AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinically significant laboratory assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 9 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD) at 9 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Fat-free Mass at 9 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaginal length between the arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased Numbers of Peptide Specific T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reported Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Weighted Sum of Temperature Differences Over 6 Hours (WSTD6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Volume of Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration time profiles under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in sleep EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Completion of Survivorship Care Plan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use